Results for: Rocatinlimab

Amgen’s rocatinlimab, an experimental drug for atopic dermatitis, showed positive results in Phase 3 trials, but the data fell short of expectations. Despite this, Goldman Sachs remains optimistic about the drug’s commercial potential due to its favorable safety profile and large target market. Amgen also reported updates on Uplizna for generalized myasthenia gravis. The stock is currently down but analysts maintain a Buy rating, with eyes on Amgen’s obesity drug AMG 133 data expected later this year.

Amgen Inc (AMGN) announced positive results from Phase 3 trials for its eczema treatment, rocatinlimab, and myasthenia gravis treatment, Uplizna (inebilizumab). While rocatinlimab showed improvement over placebo, it fell short of existing competitors like Dupixent. Uplizna, however, exceeded expectations and has potential in the myasthenia gravis market due to its less frequent dosing and potential to reduce steroid use.